Unit of Hematology, Department of Oncology, University of Torino, 10126 Turin, Italy.
Medicina (Kaunas). 2021 Aug 9;57(8):813. doi: 10.3390/medicina57080813.
Myeloproliferative neoplasms (MPNs) are clonal stem cell disorders characterized collectively by clonal proliferation of myeloid cells with variable morphologic maturity and hematopoietic efficiency. Although the natural history of these neoplasms can be measured sometimes in decades more than years, the cytogenetics analysis can offer useful information regarding the prognosis. Cytogenetics has a well-established prognostic role in acute leukemias and in myelodysplastic syndromes, where it drives the clinical decisions. NGS techniques can find adverse mutations with clear prognostic value and are currently included in the prognostic evaluation of MPNs in scores such as MIPSS, GIPSS, MIPSS-PV, and MIPSS-ET. We suggest that cytogenetics (considering its availability and relative cost) has a role regarding prognostic and therapeutic decisions.
骨髓增殖性肿瘤（MPNs）是一种克隆性干细胞疾病，其特征为骨髓细胞的克隆性增殖，具有不同程度的形态成熟和造血效率。尽管这些肿瘤的自然病史有时可以在数十年而不是数年中进行衡量，但细胞遗传学分析可以提供有关预后的有用信息。细胞遗传学在急性白血病和骨髓增生异常综合征中具有明确的预后作用，它指导着临床决策。NGS 技术可以发现具有明确预后价值的不良突变，目前已被纳入 MPN 预后评估的评分中，如 MIPSS、GIPSS、MIPSS-PV 和 MIPSS-ET。我们认为，细胞遗传学（考虑到其可用性和相对成本）在预后和治疗决策方面具有一定作用。
